Kuruvilla FG, Schreiber SL. The PIK-related kinases intercept conventional signaling pathways. Chem Biol. 1999;6(5):R129-36. doi:10.1016/S1074-5521(99)80070-2
Peterson RT, Schreiber SL. Translation control: connecting mitogens and the ribosome. Curr Biol. 1998;8(7):R248-50.
Cantley LC, Dalton WS, DuBois RN, et al. AACR Cancer Progress Report 2012. Clin Cancer Res. 2012;18(21 Suppl):S1-100. doi:10.1158/1078-0432.CCR-12-2891
Cimprich KA, Shin TB, Keith CT, Schreiber SL. cDNA cloning and gene mapping of a candidate human cell cycle checkpoint protein. Proc Natl Acad Sci U S A. 1996;93(7):2850-5.
Schreiber SL, Crabtree GR. Immunophilins, ligands, and the control of signal transduction. Harvey Lect. 1995;91:99-114.
Albers MW, Williams RT, Brown EJ, Tanaka A, Hall FL, Schreiber SL. FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line. J Biol Chem. 1993;268(30):22825-9.
Bierer BE, Mattila PS, Standaert RF, et al. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci U S A. 1990;87(23):9231-5.
Ho SN, Boyer SH, Schreiber SL, Danishefsky SJ, Crabtree GR. Specific inhibition of formation of transcription complexes by a calicheamicin oligosaccharide: a paradigm for the development of transcriptional antagonists. Proc Natl Acad Sci U S A. 1994;91(20):9203-7.
Finberg RW, Diamond DC, Mitchell DB, et al. Prevention of HIV-1 infection and preservation of CD4 function by the binding of CPFs to gp120. Science. 1990;249(4966):287-91.
Carmody LC, Germain AR, VerPlank L, et al. Phenotypic high-throughput screening elucidates target pathway in breast cancer stem cell-like cells. J Biomol Screen. 2012;17(9):1204-10. doi:10.1177/1087057112458317